Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

Boehringer Ingelheim and Eli Lilly’s heart failure drug Jardiance reduced the risk of cardiovascular death or hospitalisation due to heart failure in adult patients with and without diabetes – an important ... In March, the US Food and Drug

Latest news

  • Merck, Bayer get FDA priority review for heart failure drug Merck, Bayer get FDA priority review for heart failure drug

    Even though the drug reduced hospitalisation, the difference in cardiovascular death and all-cause mortality between the groups was not significantly different. ... The New Drug Application (NDA) filed for vericiguat is aiming for approval as a treatment

  • Amarin shares tumble following Vascepa patent loss Amarin shares tumble following Vascepa patent loss

    It became the first US Food and Drug Administration (FDA)-approved drug to reduce cardiovascular risk in patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. ... treating indicated patients at high risk of

  • Merck, Bayer flesh out vericiguat heart failure data at ACC Merck, Bayer flesh out vericiguat heart failure data at ACC

    Drug reduced rate of cardiovascular deaths and hospitalisations. Bayer and Merck &Co have unveiled the data from their phase 3 trial of vericiguat in high-risk heart failure, backing up a ... The difference in cardiovascular death and all-cause mortality

  • Lilly’s Trulicity scores CV reduction indication in the US Lilly’s Trulicity scores CV reduction indication in the US

    The US Food and Drug Administration (FDA) approval came on the back of Lilly’s REWIND study, which studied the drug in people who had cardiovascular (CV) risk factors, although most ... and without established cardiovascular disease," said Sherry Martin

  • Eisai agrees to pull obesity drug Belviq after safety alert Eisai agrees to pull obesity drug Belviq after safety alert

    The study was intended to check whether the drug was associated with any cardiovascular safety issues, but follow-up revealed “several different types of cancers occurring more frequently in the lorcaserin ... In 2010, the FDA rejected the first

More from news
Approximately 2 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... and manufacturing partner. Quillivant XR is based

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug

  • Senior AstraZeneca exec jumps ship to small biotech Senior AstraZeneca exec jumps ship to small biotech

    AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. . ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads

  • Milestone names chief medical officer Milestone names chief medical officer

    Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics